- The drug must work against the virus in cells or animal models at doses which are relevant for humans
- The amount of drug reaching the cells and organs affected by the virus must be adequate to either kill the virus and/or reduce inflammation.
- There needs to be a good understanding of how the virus infects and multiplies within the body and how this relates to the clinical features of COVID-19.
- The information from the above 3 principles should be used to define the optimal doses and duration of therapy (or therapies when more than one drug is used).
- Well-designed trials must be undertaken to show that the drug works in treating the disease and is safe.
The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the British Pharmacological Society have published a joint international statement calling on researchers to apply clinical pharmacology principles in search for safe and effective treatments for COVID-19. The statement was published in the British Journal of Clinical Pharmacology and endorsed by international organisations* across the world. The statement welcomes international efforts to safely expedite clinical trials in the search for a treatment. However, it cautions that many studies do not include the information that is needed to safely translate a promising treatment from research to clinical practice. It sets out five principles that are intended to give research efforts the best chance of success to identify potential treatments: